Opioid use disorder has reached a critical level in the United States, driven by over-prescription and diversion of opioid painkillers, as well as the low cost and increased potency of heroin. The societal impact is substantial in terms of costs related to treatment, lost work productivity, criminal activity, and social welfare expenditure. The goals of treatment for opioid use disorder include a decrease in illicit opioid use, decreased mortality, and reductions in criminal activity.

For questions or additional information, please contact info@icer.org

Interventions of interest, 2018 review:

Medications for addiction treatment using:

  • Monthly buprenorphine injection (Sublocade™, Indivior)
  • Buprenorphine implant (Probuphine®, Braeburn/Titan)
  • Buprenorphine extended release injection (CAM2038, Braeburn) currently under review by the FDA

These therapies will be compared to MAT with methadone, buprenorphine/naloxone sublingual film (Suboxone®, Indivior), and injectable naltrexone (Vivitrol®, Alkermes).

Final Documents

Below you will find the final documents from the assessment review process: